Generic Vtama Availability
Last updated on Apr 10, 2025.
Vtama is a brand name of tapinarof topical, approved by the FDA in the following formulation(s):
VTAMA (tapinarof - cream;topical)
-
Manufacturer: DERMAVANT SCI
Approval date: May 23, 2022
Strength(s): 1% [RLD]
Is there a generic version of Vtama available?
No. There is currently no therapeutically equivalent version of Vtama available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vtama. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Topical pharmaceutical compositions
Patent 10,195,160
Issued: February 5, 2019
Inventor(s): Sonti Sujatha D. & Thomas Joey Roger & Lenn Jon & Santos Leandro & Whiteman Justin & Doherty Michael Quinn & Bedard Mary & Jain Piyush
Assignee(s): Dermavant Sciences GmbHThe present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.
Patent expiration dates:
- May 19, 2036✓
- May 19, 2036
-
Topical pharmaceutical compositions
Patent 10,426,743
Issued: October 1, 2019
Inventor(s): Sonti Sujatha D. & Thomas Joey Roger & Lenn Jon & Santos Leandro & Whiteman Justin & Doherty Michael Quinn & Bedard Mary & Jain Piyush
Assignee(s): DERMAVANT SCIENCES GMBHThe present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.
Patent expiration dates:
- May 19, 2036✓
- May 19, 2036✓
- May 19, 2036
-
Process for preparing tapinarof
Patent 10,647,649
Issued: May 12, 2020
Inventor(s): Andrews Ian Paul & Calandra Nicholas & Davis Tyler Andrew & Sudini Ravinder Reddy
Assignee(s): DERMAVANT SCIENCES GMBHThe present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.
Patent expiration dates:
- November 13, 2038✓
- November 13, 2038
-
Topical pharmaceutical compositions
Patent 11,458,108
Issued: October 4, 2022
Inventor(s): Sonti; Sujatha D. et al.
Assignee(s): DERMAVANT SCIENCES GMBH (Basel, CH)The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.
Patent expiration dates:
- May 19, 2036✓
- May 19, 2036
-
Use of tapinarof for the treatment of atopic dermatitis
Patent 11,497,718
Issued: November 15, 2022
Inventor(s): Kraus; John E. et al.
Assignee(s): DERMAVANT SCIENCES GMBH (Basel, CH)Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3.
Patent expiration dates:
- November 13, 2039✓
- November 13, 2039
-
Use of Tapinarof for the treatment of chronic plaque psoriasis
Patent 11,590,088
Issued: February 28, 2023
Inventor(s): Kraus; John E. et al.
Assignee(s): DERMAVANT SCIENCES GMBH (Basel, CH)Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.
Patent expiration dates:
- November 13, 2039✓
- November 13, 2039
-
Process for preparing tapinarof
Patent 11,597,692
Issued: March 7, 2023
Inventor(s): Andrews; Ian Paul et al.
Assignee(s): DERMAVANT SCIENCES GMBH (Basel, CH)The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and novel intermediates used therein. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro-2-isopropyl-5-styrylcyclohexane-1,3-dione. Also disclosed are crystal forms of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same.
Patent expiration dates:
- November 13, 2038✓✓
- November 13, 2038
-
Topical pharmaceutical compositions
Patent 11,612,573
Issued: March 28, 2023
Inventor(s): Sonti; Sujatha D. et al.
Assignee(s): DERMAVANT SCIENCES GMBH (Basel, CH)The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.
Patent expiration dates:
- May 19, 2036✓
- May 19, 2036✓
- May 19, 2036
-
Topical pharmaceutical compositions
Patent 11,617,724
Issued: April 4, 2023
Inventor(s): Sonti; Sujatha D. et al.
Assignee(s): DERMAVANT SCIENCES GMBH (Basel, CH)The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.
Patent expiration dates:
- May 19, 2036✓
- May 19, 2036
-
Topical pharmaceutical compositions
Patent 11,622,945
Issued: April 11, 2023
Inventor(s): Sonti; Sujatha D. et al.
Assignee(s): DERMAVANT SCIENCES GMBH (Basel, CH)The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.
Patent expiration dates:
- May 19, 2036✓
- May 19, 2036
-
Use of tapinarof for the treatment of atopic dermatitis
Patent 11,938,099
Issued: March 26, 2024
Inventor(s): Kraus; John E. et al.
Assignee(s): DERMAVANT SCIENCES GMBH (Basel, CH)Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.
Patent expiration dates:
- November 13, 2039✓
- November 13, 2039
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 23, 2027 - NEW CHEMICAL ENTITY
- December 12, 2027 - TREATMENT OF ATOPIC DERMATITIS IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
More about Vtama (tapinarof topical)
- Compare alternatives
- Pricing & coupons
- Reviews (36)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical antipsoriatics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
